NASDAQ:ZVRA Zevra Therapeutics Q2 2026 Earnings Report $9.52 -3.00 (-23.96%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$9.54 +0.03 (+0.26%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Zevra Therapeutics EPS ResultsActual EPSN/AConsensus EPS $0.08Beat/MissN/AOne Year Ago EPSN/AZevra Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$33.88 millionBeat/MissN/AYoY Revenue GrowthN/AZevra Therapeutics Announcement DetailsQuarterQ2 2026Date8/5/2026TimeAfter Market ClosesConference Call DateWednesday, August 5, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Zevra Therapeutics Earnings HeadlinesZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 25 at 2:15 AM | americanbankingnews.comZevra Therapeutics Receives EMA Negative Opinion on Arimoclomol Marketing ApplicationJuly 24 at 12:50 AM | finance.yahoo.comAmerica Is Following in Greece's FootstepsItaly in the 90s. Argentina in 2001. Greece in 2009. America was always safe… But now the IMF is projecting that by 2031, US debt will climb to 140% of GDP. That's higher than Greece's debt was when their entire economy collapsed. When Greece broke, the EU swooped in with $300 billion in emergency bailouts. Greece was fine. But when America crosses that line? There's no one bigger to save us. We ARE the emergency bailout for the rest of the world. You can't fix $38 trillion in debt. You can't stop Congress from spending. But you CAN control how much of your wealth stays exposed to the fallout. | Decentralized Masters (Ad)ZVRA stock sinks 23% on EU setback — analyst says risk is 'a headwind, but not insurmountable'July 24 at 12:50 AM | msn.comZevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type CJuly 24 at 12:47 PM | benzinga.comZVRA stock plummets pre-market, heads for worst day in over 5 years – what’s driving the sell-off?July 24 at 9:43 AM | msn.comSee More Zevra Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zevra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zevra Therapeutics and other key companies, straight to your email. Email Address About Zevra TherapeuticsZevra Therapeutics (NASDAQ:ZVRA) discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.View Zevra Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks HealthierAMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyDefense Earnings Show Readiness Now and Modernization AheadFreeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good EnoughTesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Upcoming Earnings Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026)Rio Tinto (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
